Abstract
Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthritis (psoriatic arthritis) and mental disorders. Furthermore, an association with cardiovascular events is indicated. With the advent of biologics, treatment of psoriasis dramatically changed due to its high efficacy and tolerable safety. A variety of biologic agents are available for the treatment of psoriasis nowadays. However, characteristics such as rapidity of onset, long-term efficacy, safety profile, and effects on comorbidities are different. Better understanding of those characteristic leads to the right choice for individual patients, resulting in higher persistence, longer drug survival, higher patient satisfaction, and minimizing the disease impact of psoriasis. In this paper, we focus on the efficacy and safety profile of biologics in psoriasis patients, including plaque psoriasis and psoriatic arthritis. In addition, we discuss the impact of biologics on comorbidities caused by psoriasis.
Highlights
Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema
We focus on the efficacy and safety profile of biologics in psoriasis patients, including plaque psoriasis and PsA
Sawyer et al performed a network meta-analysis including 77 trials (34,816 patients) [28]. They revealed the superiority of brodalumab, ixekizumab, secukinumab, guselkumab and risankizumab to tildrakizumab, ustekinumab, all tumor necrosis factor (TNF)-α inhibitors, and non-biologic systemic treatments in efficacy for plaque psoriasis
Summary
Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. The prevalence of psoriasis in children ranges from 0% (Taiwan) to 2.1% (Italy), and in adults it varies from 0.91% (United States) to 8.5% (Norway) [1]. It impairs patients’ quality of life enormously. It has been recognized as a skin disease but as a systemic disease, since it causes arthritis (psoriatic arthritis; PsA) and mental disorders. With the advent of biologics, treatment of psoriasis dramatically changed due to its high efficacy and tolerable safety. We discuss the impact of biologics on comorbidities caused by psoriasis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
